The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; ASKA Pharmaceutical; Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EA Pharma; EI Dupont; Eisai; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan Pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Otsuka; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda
Consulting or Advisory Role - Bayer Yakuhin; Hokkoku Bank; Kowa
Research Funding - Abbott Vascular (Inst); Abbvie (Inst); Alexion Pharmaceuticals (Inst); ASKA Pharmaceutical (Inst); Astellas Pharma (Inst); Bayer Yakuhin (Inst); Biotronik International (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Central Medical (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Japan Lifeline (Inst); Kataoka (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Medtronic (Inst); Mitsubishi Tanabe Pharma (Inst); MSD (Inst); Mylan (Inst); Nihon Medi-Physics (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanarus Medical (Inst); Sanofi (Inst); Shionogi (Inst); St. Jude Medical (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); TERUMO (Inst); Tomiki Medical Instruments (Inst); Zeon Medical (Inst); Zeria Pharmaceutical (Inst)
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Max W. Sung
Consulting or Advisory Role - Bayer; Eisai
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Masahiro Kobayashi
Honoraria - Abbvie; EA Pharma; Eisai; Gilead Sciences; Nippon Kayaku; Sumitomo Dainippon
 
Ari David Baron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Shuichi Kaneko
No Relationships to Disclose
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Sanofi
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Tomoki Kubota
Employment - Eisai
 
Silvija Kraljevic
Employment - Eisai
 
Kohei Ishikawa
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Hiromitsu Kumada
Honoraria - Abbvie; Ajinomoto; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen; Kowa; Mitsubishi Tanabe Pharma; Otsuka; Sumitomo Chemical; Toray Industries; Toray Industries
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Lilly Japan; Nippon Chemiphar; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Sumitomo Dainippon; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - Daiichi Sankyo; Sumitomo Dainippon; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Baxter (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)